The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Background GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE)
in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists …

Background We aimed to assess efficacy and safety, with a special focus on cardiovascular
safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Nearly half of all adults with type 2 diabetes mellitus (T2DM) live in India and China. These
populations have an underlying predisposition to deficient insulin secretion, which has a key …